This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
WALTHAM, Mass., March 1, 2013 (GLOBE NEWSWIRE) -- Repligen Corporation (Nasdaq:RGEN) announced today that it will report financial results for the fourth quarter and year ended December 31, 2012 on March 7. On this date, the Company will issue a press release prior to the opening of the NASDAQ Global Market, followed by a conference call and webcast at 9:00 a.m. EST to discuss financial results for the reporting period. The event will be hosted by Walter C. Herlihy, Ph.D., President and CEO of Repligen.
Repligen's fourth quarter and year end conference call will be accessible by dialing
(800) 291-5365 for domestic callers or
(617) 614-3922 for international callers. Dial-in participants must provide the passcode
66969032. Alternatively, an audio webcast will be accessible via the Investors section of Repligen's website
www.repligen.com . Both the conference call and webcast will be archived for a period of time following the live event. The replay dial-in numbers are (888) 286-8010 for domestic callers and (617) 801-6888 for international callers. Replay listeners must provide the passcode 97774715.
About Repligen Corporation
Repligen Corporation (Nasdaq:RGEN) is a life sciences company focused on the development, production and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. We are a leading manufacturer of Protein A, a critical reagent used to separate and purify monoclonal antibody therapeutics. We also supply several growth factor products used to increase cell culture productivity during the fermentation stage of drug manufacturing. In addition, we have developed and market our OPUS® series of pre-packed "plug-and-play" chromatography columns, and we provide test kits to ensure final product quality. Aside from our core bioprocessing business, we have a portfolio of clinical-stage partnering assets, including a pancreatic imaging agent in Phase 3 development and a orphan drug candidate in Phase 1 development. Repligen's corporate headquarters are located in Waltham, MA (USA) and our manufacturing facilities are located in Waltham, MA and Lund, Sweden.